Tasly Pharmaceutical Group Co Ltd (600535):企業の財務・戦略的SWOT分析

◆英語タイトル:Tasly Pharmaceutical Group Co Ltd (600535) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C12930
◆発行会社(調査会社):GlobalData
◆発行日:2019年1月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Tasly Pharmaceutical Group Co Ltd (600535) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Tasly Pharmaceutical Group Co Ltd (Tasly), formerly Tianjin Tasly Pharmaceutical Co., Ltd., manufactures and distributes chemical medicine, biological medicine, healthcare products, traditional Chinese medicine (TCM), functional food and other products. The company’s product line includes herbal medicine, chemical medicine, health product, pharmaceutical substances and active pharmaceutical ingredients (APIs), herbal extract, tea, cosmetics, daily hygiene product series and medical equipment. It markets its products in domestic market through its own sales force and through distributors and subsidiaries in Malaysia, Indonesia, Vietnam, South Korea, Pakistan, Thailand, Istanbul, Botswana, South Africa, Ghana, Kenya, Zambia, Nigeria, Russia, Netherlands, Bahamas and the US. Tasly is headquartered in Tianjin, China.

Tasly Pharmaceutical Group Co Ltd Key Recent Developments

Sep 17,2018: TOPC : Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast[Newswire : MarketLine - GNW]

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Tasly Pharmaceutical Group Co Ltd – Key Facts 5
Tasly Pharmaceutical Group Co Ltd – Key Employees 6
Tasly Pharmaceutical Group Co Ltd – Major Products and Services 7
Tasly Pharmaceutical Group Co Ltd – History 10
Tasly Pharmaceutical Group Co Ltd – Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Joint Venture 12
Section 2 – Company Analysis 13
Company Overview 13
Tasly Pharmaceutical Group Co Ltd – Business Description 14
Tasly Pharmaceutical Group Co Ltd – Corporate Strategy 16
Tasly Pharmaceutical Group Co Ltd – SWOT Analysis 17
SWOT Analysis – Overview 17
Tasly Pharmaceutical Group Co Ltd – Strengths 17
Tasly Pharmaceutical Group Co Ltd – Weaknesses 18
Tasly Pharmaceutical Group Co Ltd – Opportunities 19
Tasly Pharmaceutical Group Co Ltd – Threats 20
Tasly Pharmaceutical Group Co Ltd – Key Competitors 21
Section 3 – Company Financial Ratios 22
Financial Ratios – Capital Market Ratios 22
Financial Ratios – Annual Ratios 23
Performance Chart 26
Financial Performance 26
Financial Ratios – Interim Ratios 27
Financial Ratios – Ratio Charts 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances 29
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 29
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019 30
Tasly Pharmaceutical Group Co Ltd, Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
Sep 17, 2018: TOPC : Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast[Newswire : MarketLine - GNW] 32
Section 6 – Appendix 33
Methodology 33
Ratio Definitions 33
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Tasly Pharmaceutical Group Co Ltd, Key Facts 5
Tasly Pharmaceutical Group Co Ltd, Key Employees 6
Tasly Pharmaceutical Group Co Ltd, Major Products and Services 7
Tasly Pharmaceutical Group Co Ltd, History 10
Tasly Pharmaceutical Group Co Ltd, Subsidiaries 12
Tasly Pharmaceutical Group Co Ltd, Joint Venture 12
Tasly Pharmaceutical Group Co Ltd, Key Competitors 21
Tasly Pharmaceutical Group Co Ltd, Ratios based on current share price 22
Tasly Pharmaceutical Group Co Ltd, Annual Ratios 23
Tasly Pharmaceutical Group Co Ltd, Annual Ratios (Cont...1) 24
Tasly Pharmaceutical Group Co Ltd, Annual Ratios (Cont...2) 25
Tasly Pharmaceutical Group Co Ltd, Interim Ratios 27
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 29
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019 30
Tasly Pharmaceutical Group Co Ltd, Recent Deals Summary 31
Currency Codes 33
Capital Market Ratios 33
Equity Ratios 34
Profitability Ratios 34
Cost Ratios 35
Liquidity Ratios 35
Leverage Ratios 36
Efficiency Ratios 36

List of Figures
Tasly Pharmaceutical Group Co Ltd, Performance Chart (2013 - 2017) 26
Tasly Pharmaceutical Group Co Ltd, Ratio Charts 28
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 29
Tasly Pharmaceutical Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019 30

★海外企業調査レポート[Tasly Pharmaceutical Group Co Ltd (600535):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Investitionsbank Berlin:企業の戦略・SWOT・財務分析
    Investitionsbank Berlin - Strategy, SWOT and Corporate Finance Report Summary Investitionsbank Berlin - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Pakistan Water and Power Development Authority:電力:M&Aディール及び事業提携情報
    Summary Pakistan Water and Power Development Authority (WAPDA) is a government-owned public authority maintaining power and water in Pakistan. It is responsible for the development of hydel power and water sector projects in Pakistan. The authority plans and executes projects and schemes for the gen …
  • SAS AB:戦略・SWOT・企業財務分析
    SAS AB - Strategy, SWOT and Corporate Finance Report Summary SAS AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Humanigen Inc (HGEN)-製薬・医療分野:企業M&A・提携分析
    Summary Humanigen Inc(Humanigen) formerly known as KaloBios Pharmaceuticals Inc, is a development stage biopharmaceutical company that develops medicines for neglected and rare diseases. The company offers benznidazole, a nitroimidazole derivative used for the treatment of Chagas disease, a parasiti …
  • L-3 Unmanned Systems, Inc.:企業の戦略・SWOT・財務情報
    L-3 Unmanned Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary L-3 Unmanned Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Genome Institute of Singapore:製薬・医療:M&Aディール及び事業提携情報
    Summary Genome Institute of Singapore (GIS) is a research institute that provides research programs and services in different areas. The institute concentrates on genomic sciences to improve public health and prosperity in Singapore. It operates technology and comprises early career researchers such …
  • Cypress Energy Partners LP (CELP):企業の財務・戦略的SWOT分析
    Summary Cypress Energy Partners LP (Cypress Energy), a subsidiary of Cypress Energy Holdings LLC, is an energy services company that provides midstream services. The company provides services such as pipeline inspection, integrity and hydrostatic testing services to energy, exploration and productio …
  • Ackermans & Van Haaren NV:戦略・SWOT・企業財務分析
    Ackermans & Van Haaren NV - Strategy, SWOT and Corporate Finance Report Summary Ackermans & Van Haaren NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • PhotoMedex Inc (PHMD)-医療機器分野:企業M&A・提携分析
    Summary PhotoMedex Inc (PhotoMedex) is a medical device company that provides dermatological solutions. The company offers Neova, Tricomin and IAMIN products. Its products are used in the treatment of skin diseases and conditions such as psoriasis, vitiligo, acne, actinic keratosis. PhotoMedex provi …
  • Copperbelt Energy Corporation PLC (CEC)-エネルギー分野:企業M&A・提携分析
    Summary Copperbelt Energy Corporation PLC (CEC) is an electric utility that generates, transmits, distributes and sells energy. The company generates electricity from hydro, solar, gas and thermal sources; transmits electricity through a network of transmission lines and high voltage substations and …
  • United Orthopedic Corp (4129)-医療機器分野:企業M&A・提携分析
    Summary United Orthopedic Corp (UOC) is a medical device company that designs, manufactures and distributes orthopedic implants and instrument sets. The company’s product categories include knee replacement systems, hip replacement systems, and oncology products. Its hip replacement systems include …
  • Porsche Automobil Holding SE (PAH3):企業の財務・戦略的SWOT分析
    Porsche Automobil Holding SE (PAH3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Siemens Healthineers AG (SHL):企業の財務・戦略的SWOT分析
    Siemens Healthineers AG (SHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Paramo AS:企業の戦略的SWOT分析
    Paramo AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Anadarko Petroleum Corp (APC):企業の財務・戦略的SWOT分析
    Anadarko Petroleum Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Silence Therapeutics Plc (SLN)-製薬・医療分野:企業M&A・提携分析
    Summary Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a research and development company that develops and delivers RNA interference therapeutics for the treatment of serious diseases. The company's pipeline products include Atu027 and Atu111. Its Atu027 is developed for …
  • Universiteit Utrecht-製薬・医療分野:企業M&A・提携分析
    Summary Universiteit Utrecht (Universiteit Utrecht) is a research university that offers education programs. The university offers bachelors, master's, honor education, education for professionals, online education, training and other education courses. Its research areas include earth and sustainab …
  • Healthcare Services Group Inc (HCSG):企業の財務・戦略的SWOT分析
    Healthcare Services Group Inc (HCSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • The Bidvest Group Ltd:企業のM&A・事業提携・投資動向
    The Bidvest Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Bidvest Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • AcelRx Pharmaceuticals Inc (ACRX):製薬・医療:M&Aディール及び事業提携情報
    Summary AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo outside the US), is a single sufentanil sublingual tablet for the treatment of moderate-t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆